TacticScaleWhat Elanco Animal Health Does & How It Makes Money (ELAN)
Updated October 2026 · reflects Elanco Animal Health's latest reported financials
Animal health company making medicines and parasite treatments for pets and livestock. Elanco earns revenue by selling branded animal health products to third-party distributors and independent retailers, and directly to veterinarians and farm animal producers.
How Elanco Animal Health makes money
Elanco earns revenue by selling branded animal health products to third-party distributors and independent retailers, and directly to veterinarians and farm animal producers. Sales come from two segments: pet health and farm animal health.
What Elanco Animal Health does
Elanco Animal Health, founded in 1954 and headquartered in Indianapolis, is a pure-play animal health company serving both pets and farm animals worldwide. Its pet health business centers on parasite protection, including well-known brands such as Seresto collars, K-9 Advantage, Advantix, Advocate, Credelio, and Interceptor Plus. It also offers vaccines and therapeutics for pain, otitis, cardiovascular, and dermatology conditions, including Galliprant for osteoarthritis in dogs and cats. On the farm animal side, Elanco sells medicated feed additives, injectable antibiotics, vaccines, insecticides, and enzymes for cattle, swine, and poultry under brands like Rumensin, Baytril, Experior, Maxiban, and Monteban. It reaches customers through distributors and retailers and also sells directly to veterinarians and livestock producers, so its results depend on both consumer spending on pets and demand from livestock farming.
Products & services
- Seresto
- Credelio Family
- Interceptor Plus
- Galliprant
- Rumensin
- Advantage/Advantix
What is Elanco Animal Health worth?
On an owner-earnings DCF, Elanco Animal Health's most-likely value is about $16 versus a recent price near $23 (29% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$8) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 8.8× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Zoetis (ZTS) · Phibro Animal Health (PAHC) · Amneal Pharmaceuticals (AMRX) · ANI Pharmaceuticals (ANIP)